Ascendis Pharma announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion and recommended the approval of TransCon PTH as a parathyroid hormone replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. The European Commission’s final decision on the company’s marketing authorization application is expected within 67 days after the positive opinion.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ASND:
- Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism
- Biotech Alert: Searches spiking for these stocks today
- Ascendis Stock (NASDAQ:ASND): Investors and Analysts are Bullish Post Q2 Results
- Ascendis Pharma price target raised to $113 from $107 at BofA
- Ascendis Pharma price target raised to $192 from $187 at Wedbush